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Summary
Background.  —  The  association  between  obstructive  sleep  apnoea  syndrome  (OSAS),  left  ven-
tricular (LV)  diastolic  dysfunction  and  LV  geometry  remains  controversial  because  of  coexisting
disorders.
Abbreviations: A, late diastolic mitral peak ﬂow velocity; AASM, American Academy of Sleep Medicine; ABPM, ambulatory blood pressure
onitoring; AH, apnoea-hypopnoea; AHI, apnoea-hypopnoea index; BMI, body mass index; BSA, body surface area; CPAP, continuous positive
irway pressure; DBP, diastolic blood pressure; E, early diastolic mitral peak ﬂow velocity; e′, early diastolic mitral annular velocity; ECG,
lectrocardiogram; LAA, left atrial area; LV, left ventricular; LVEF, left ventricular ejection fraction; LVH, left ventricular hypertrophy; LVM,
eft ventricular mass; LVMi, left ventricular mass index; OSAS, obstructive sleep apnoea syndrome; PHT, pulmonary hypertension; RWT,
elative wall thickness; SDB, systolic blood pressure; sPAP, systolic pulmonary arterial pressure; TDI, tissue Doppler imaging.
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Aims.  —  To  evaluate  LV  diastolic  dysfunction  and  its  independent  predictors  in  a  real-life  cohort
of OSAS  patients,  by  a  standardized  approach.
Methods.  —  We  consecutively  included  188  OSAS  patients  after  an  overnight  polysomnography  to
undergo clinical  evaluation,  ambulatory  blood  pressure  measurement  and  complete  echocar-
diography,  combining  M-mode,  two-dimensional  Doppler  and  tissue  Doppler  imaging  modes.
Correlations  between  OSAS  severity  and  clinical  and  echocardiographical  variables  were
assessed,  and  logistic  regression  models  were  used  to  identify  possible  determining  factors
of LV  diastolic  dysfunction.
Results.  —  Most  patients  were  hypertensive  (n  =  148,  78.7%)  and  already  receiving  treatment
by continuous  positive  airway  pressure  (n  =  158,  84.5%).  The  prevalence  of  LV  hypertrophy,
deﬁned by  LV  mass  index  (LVMi)  normalized  by  height2.7,  was  12.4%,  with  a  signiﬁcant  correla-
tion with  hypertension  (P  =  0.004).  The  apnoea-hypopnoea  index  was  correlated  with  body  mass
index (P  <  0.0001),  24-hour  systolic  blood  pressure  (P  =  0.01)  and  LVMi  normalized  by  height2.7
(P  =  0.03).  Diastolic  function  assessed  by  a  global  approach  was  impaired  for  70  patients  (37.2%)
and none  of  the  OSAS  severity  variables  was  a  determining  factor  after  multivariable  analysis
with adjustment  for  age  and  sex.
Conclusion.  —  Diastolic  dysfunction  assessed  by  a  standardized  approach  is  common  in  OSAS  and
should be  routinely  evaluated;  it  is  independently  predicted  by  none  of  the  respiratory  severity
variables.
© 2015  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé
Contexte.  —  L’association  entre  le  syndrome  d’apnée  du  sommeil  obstructif  (SASO),  la  dysfonc-
tion diastolique  ventriculaire  gauche  (VG)  et  la  géométrie  VG  reste  controversée  en  raison  de
nombreux  facteurs  prédisposants  partagés.
Objectifs.  —  Évaluer  la  fonction  diastolique  VG  et  ses  déterminants  dans  une  cohorte  de  patients
SASO tout-venant,  par  une  approche  standardisée.
Méthodes.  —  Après  polysomnographie,  188  patients  consécutifs  ont  eu  un  bilan  cardiovasculaire
avec évaluation  clinique,  mesure  ambulatoire  de  la  pression  artérielle,  et  échocardiographie
avec modes  TM,  2D,  doppler,  et  doppler  tissulaire.  Les  corrélations  entre  sévérité  du  SASO  et
les paramètres  cliniques  et  échographiques  ont  été  analysées.  Les  potentiels  déterminants  de
la dysfonction  diastolique  VG  ont  été  étudiés  par  régression  logistique.
Résultats.  —  La  plupart  des  patients  étaient  hypertendus  (n  =  148,  78,7  %)  et  étaient  déjà  traités
par ventilation  en  pression  positive  continue  (n  =  158,  84,5  %).  La  prévalence  de  l’hypertrophie
VG établie  sur  la  masse  VG  indexée  à  la  taille2,7 (MVGi)  était  de  12,4  %  avec  une  corrélation
signiﬁcative  avec  l’hypertension  (p  =  0,004).  L’index  apnée-hypopnée  était  corrélé  à  l’indice  de
masse corporelle  (p  <  0,0001),  la  pression  systolique  des  24  h  (p  =  0,01)  et  la  MVGi  (p  =  0,03).  La
fonction  diastolique  étudiée  par  approche  standardisée  était  anormale  pour  70  (37,2  %)  patients.
Aucun des  paramètres  de  sévérité  du  SASO  n’était  prédicteur  indépendant  de  dysfonction
diastolique  après  analyse  multivariée  ajustée  sur  l’âge  et  le  sexe.
Conclusion.  — La  dysfonction  diastolique  est  fréquente  chez  les  patients  SASO  et  doit  être
recherchée  en  routine.  Elle  n’est  prédite  de  fac¸on  indépendante  par  aucun  des  paramètres
de sévérité  respiratoires.
© 2015  Elsevier  Masson  SAS.  Tous  droits  réservés.
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Obstructive  sleep  apnoea  syndrome  (OSAS)  is  a  common
chronic  respiratory  sleep  disorder  characterized  by  periodic
reduction  or  cessation  of  breathing  due  to  narrowing  of  the
upper  airways  during  sleep;  it  occurs  in  2%  of  middle-aged
women  and  4%  of  men  [1].  OSAS  is  a  well-established  risk  fac-
tor  for  several  cardiovascular  complications,  including  heart
a
aailure  [2], acute  myocardial  infarction  [3], arrhythmias  [4],
ypertension  [5],  pulmonary  hypertension  [6]  and  stroke
7]. The  pathophysiological  effects  of  obstructive  apnoea
n  the  cardiovascular  system  involve  several  mechanical,
aemodynamic,  neurohumoral,  inﬂammatory,  endothelial
nd  oxidative  mechanisms  [8].
In  addition,  left  ventricular  hypertrophy  (LVH),  which  is
ssociated  with  left  ventricular  (LV)  diastolic  dysfunction
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9],  is  often  observed  in  OSAS  patients.  LV  diastolic  dys-
unction  is  also  known  to  be  an  independent  risk  factor
or  cardiovascular  morbidity  and  mortality  [10],  like  LVH
nd  concentric  remodelling  [11].  Whereas  the  association
etween  OSAS  and  some  cardiovascular  complications  is
lear,  the  association  between  OSAS  on  the  one  hand  and  LVH
r  LV  diastolic  dysfunction  on  the  other,  still  remains  contro-
ersial  [12—15],  because  of  several  coexisting  disorders  that
ead  to  LVH  and  LV  diastolic  dysfunction,  such  as  obesity  [16],
ypertension  [17]  and  diabetes  mellitus  [18]. Moreover,  to
ur  knowledge,  previous  studies  that  investigated  the  rela-
ionship  between  OSAS  and  LV  diastolic  dysfunction  all  used
eparated  criteria,  with  no  global  approach.
The  aim  of  this  study  was  to  evaluate  the  prevalence
f  LV  diastolic  dysfunction  and  to  identify  its  determin-
ng  factors,  in  a  real-life  large  cohort  of  OSAS  patients,
y  an  echocardiographic  multivariable  approach  using  two-
imensional  mode  Doppler,  conventional  Doppler  and  tissue
oppler  imaging  (TDI).
ethods
opulation
e  conducted  an  observational  cohort  study  in  188  patients
ith  OSAS  who  were  referred  consecutively  by  Saint-
ntoine’s  Sleep  Laboratory  (Paris,  France)  for  cardiovascular
valuation  between  March  2005  and  January  2010.  There
ere  no  exclusion  criteria.  After  sleep  study  in  Saint-
ntoine’s  expertise  centre,  each  patient  underwent  a
linical  evaluation  during  a  consultation,  an  electrocardio-
ram  (ECG),  24-hour  ambulatory  blood  pressure  monitoring
ABPM),  biological  tests  and  transthoracic  echocardiography.
emographic  characteristics,  measure  of  daytime  sleepi-
ess  by  the  Epworth  sleepiness  scale  and  cardiovascular  risk
actors  (including  hypertension,  diabetes  mellitus,  hyper-
ipidaemia,  current  or  former  smoking,  coronary  heredity
nd  obesity)  were  reported.  Hypertension  was  deﬁned  as
he  use  of  antihypertensive  medication  and/or  systolic  blood
ressure  (SBP)  ≥140  mmHg  and/or  diastolic  blood  pressure
DBP)  ≥90  mmHg  during  consultation  and/or  blood  pres-
ure  ≥125/80  mmHg  during  ABPM  [19].  A  dipper  pattern  was
eﬁned  by  a  nocturnal  fall  in  blood  pressure  ≥10%.  Noctur-
al  hypertension  was  deﬁned  as  nocturnal  blood  pressure
120/70  mmHg;  diurnal  hypertension  was  deﬁned  as  diurnal
lood  pressure  ≥130/85  mmHg.  Masked  hypertension  was
onsidered  to  be  present  when  normal  blood  pressure  dur-
ng  consultation  was  associated  with  hypertension  on  ABPM.
besity  was  deﬁned  as  a  body  mass  index  (BMI)  ≥30  kg/m2;
etabolic  syndrome  was  deﬁned  according  to  the  National
holesterol  Education  Program  —  Adult  Treatment  Panel  III
uidelines  [20].  According  to  the  Declaration  of  Helsinki,  all
nformation  about  participation  in  non-interventional  clini-
al  studies  was  given  to  the  patients.
leep studyll  participants  were  referred  after  an  attended  overnight
olysomnography  using  the  Cidelec® system  (Angers,
rance),  which  conﬁrmed  the  diagnosis  of  OSAS  accord-
ng  to  the  recommendations  of  the  American  Academy  of
(
t
f
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leep  Medicine  (AASM)  [21]. The  following  channels  were
sed:  two-channel  electroencephalogram,  electromyogram,
CG,  electro-oculogram,  body  position,  chest  and  abdom-
nal  excursions,  airﬂow  (with  an  oronasal  transducer)  and
rterial  oxygen  saturation  by  ﬁnger  pulse  oximetry.  Apnoea
as  deﬁned  as  a  complete  cessation  of  airﬂow  at  the  nose
nd  mouth  for  at  least  10  seconds,  and  was  classiﬁed  as
bstructive,  central  or  mixed,  according  to  the  presence
r  absence  of  respiratory  efforts.  Hypopnoea  was  deﬁned
s  a  partial  closure,  resulting  in  a  diminution  of  airﬂow  to
50%  of  baseline  for  at  least  10  seconds  or  <70%  associated
ith  a  microarousal  or  oxygen  desaturation  of  >3%.  The
pnoea-hypopnoea  index  (AHI)  was  deﬁned  as  the  number
f  apnoeas  and  hypopnoeas  per  hour  of  sleep.  Accord-
ng  to  the  AASM,  the  severity  of  OSAS  was  classiﬁed  as
ild  (5  ≤  AHI  <  15  events/hour),  moderate  (15  ≤  AHI  ≤30
vents/hour)  and  severe  (AHI  >30  events/hour).  Desatura-
ion  time  was  deﬁned  as  the  percentage  of  sleep  time  with
xygen  saturation  <90%.
chocardiography
ransthoracic  echocardiography  was  performed  with
ingmed  Vivid  7  (GE  Healthcare,  Horton,  Norway)  and  iE33
Philips  Healthcare,  Bothell,  WA,  USA)  ultrasound  machines,
ith  a  2.5  MHz  probe.  LV  dimensions  and  wall  thickness  were
easured  according  to  American  Society  of  Echocardiogra-
hy  recommendations  [22],  from  the  parasternal  long-axis
iew  using  M-mode  measurements.  Left  ventricular  mass
LVM)  was  calculated  by  the  formula  described  by  de  Simone
t  al.  [23]  and  was  normalized  by  body  surface  area  (BSA)
nd  height2.7. According  to  the  European  recommendations
24], LVH  was  deﬁned  as  an  LVM  index  (LVMi)  >115  g/m2 for
en  and  >95  g/m2 for  women  or  >50  g/m2.7 for  both;  LVH
as  deﬁned  as  concentric  if  relative  wall  thickness  (RWT)
as  >0.42  and  as  eccentric  if  RWT  was  ≤0.42.  Concentric
emodelling  was  deﬁned  as  a  normal  LVM  associated  with
n  RWT  >0.42.  LV  systolic  function  was  evaluated  by  LV
jection  fraction  (LVEF)  by  the  biplane  Simpson  method
rom  the  apical  four-chamber  and  two-chamber  views;  it
as  considered  abnormal  if  <50%.  To  evaluate  LV  diastolic
unction,  transmitral  pulsed-wave  Doppler  velocities  and
ulmonary  venous  ﬂow  were  recorded  from  the  apical
our-chamber  view,  with  a  2  mm  Doppler  sample  placed,
espectively,  between  the  tips  of  the  mitral  leaﬂets  and  in
ne  upper  pulmonary  vein  (usually  the  right);  pulsed-wave
DI  was  recorded  at  the  lateral  mitral  annulus  from  the  api-
al  four-chamber  view,  using  pulsed-wave  spectral  Doppler.
arly  diastolic  mitral  annular  velocity  (e′) was  measured
nd  the  early  diastolic  mitral  peak  ﬂow  velocity/e′ ratio
E/e′)  was  calculated.  Left  atrial  area  (LAA)  and  volume
LAV)  were  evaluated  from  the  apical  four-chamber  and
wo-chamber  views.  LV  diastolic  function  was  assessed
y  a  multivariable  approach,  adapted  from  the  American
ociety  of  Echocardiography  recommendations,  based  on
ateral  e′, LAA,  E/A  ratio  (where  A  is  late  diastolic  mitral
eak  ﬂow  velocity),  E-wave  deceleration  time,  E/e′ ratio
nd  pulmonary  venous  ﬂow  [25]. Systolic  (sPAP)  and  mean
mPAP)  pulmonary  arterial  pressure  were  calculated  using
he  modiﬁed  Bernoulli  equation  and  conventional  Doppler
rom  the  physiological  tricuspid  and  pulmonary  regurgita-
ions,  respectively  [26,27]. Patients  with  sPAP  ≥45  mmHg
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Table  1  Baseline  clinical  characteristics.
Characteristic  OSAS  patients  (n  =  188)
Men  157  (83.5)
Age  (years)  51.5  (46.0—57.0)
Hypertension  148  (78.7)
Known
hypertension
70  (47.2)
Masked
hypertension
44  (23.4)
Nocturnal
hypertension
(n  =  185)
112  (60.5)a
Diurnal
hypertension
120  (63.8)
Non-dipper
(n  =  185)
90  (48.7)a
Diabetes  23  (12.5)
Metabolic  syndrome 80 (42.6)
Current  smoker  48  (25.5)
Obesity  105  (55.9)
BMI  (kg/m2) 31.5  (27.3—35.2)
Fasting  glycaemia
(mmol/L;  n  =  183)
5.3 (4.9—5.7)a
Triglycerides  (g/L;
n  =  184)
1.21  (0.96—1.78)a
Creatinine  (mol/L;
n  =  185)
94  (86—103)a
OSAS  treatment,  yes  165  (87.8)
Treatment  with
CPAP  (n  =  187)
158 (84.5)
AHI  (events/hour)  48.4  (32.0—71.0)
Desaturation  time
(%;  n  =  180)
8 (2.0—25.5)a
Epworth  sleepiness
score  (n  =  178)
11  (7—15)
24-hour  heart  rate
(bpm)
74  (68—82)
24-hour  SBP  (mmHg)  130  (122—140)
24-hour  DBP  (mmHg)  78  (74—84)
Data are expressed as number (%) or median (interquartile
range). AHI: apnoea-hypopnoea index; BMI: body mass index;
bpm: beats per minute; CPAP: continuous positive airway
pressure; DBP: diastolic blood pressure; OSAS: obstructive sleep
apnoea syndrome; SBP: systolic blood pressure.
a
eLeft  ventricular  diastolic  function  in  obstructive  sleep  apnoe
and/or  mean  pulmonary  arterial  pressure  ≥25  mmHg
were  considered  to  have  pulmonary  hypertension  (PHT).
All  echocardiograms  were  performed  by  an  experienced
echocardiographer.  All  measurements  were  performed
off-line  using  custom  software  (Echopac;  GE  Healthcare),
in  three  cardiac  cycles,  by  the  same  investigator,  who  was
blinded  to  the  patient’s  data.
Statistical analyses
Data  are  presented  as  medians  with  interquartile  ranges.
Comparisons  between  patients  with  or  without  LVH  in  rela-
tion  to  arterial  hypertension,  diabetes  and  BMI  were  made
using  the  2 test  or  Fisher’s  exact  test.  Spearman’s  corre-
lation  analysis  was  used  to  assess  the  possible  relationship
between  severity  of  OSAS  and  clinical  or  echocardiographic
variables.  To  identify  determining  factors  of  LV  diastolic  dys-
function,  logistic  regression  models  were  used.  For  each
continuous  variable,  the  choice  between  continuous,  cate-
gorical  or  transformed  classiﬁcation  was  based  on  the  lowest
value  of  Akaike’s  information  criterion  for  the  corresponding
univariate  logistic  regression  model.  To  avoid  the  colinearity
problem  in  the  models,  the  different  variables  linked  to  a
given  entity  were  grouped  together  in  a  family  (e.g.  hyper-
tension  and  24-hour  SBP),  as  recommended  [28];  then,  each
variable  in  a  given  family  was  entered  in  a  stepwise  mul-
tivariable  model,  and  variables  with  P-values  <0.10  were
retained.  Finally,  a  multivariable  model  adjusted  for  all
selected  variables  was  constructed.  A  P-value  <0.05  was
considered  to  be  statistically  signiﬁcant  for  all  analyses.  All
statistical  analyses  were  performed  using  STATA® software,
version  12  (StataCorp  LP,  College  Station,  TX,  USA).
Results
Clinical characteristics
Between  March  2005  and  January  2010,  188  consecutive
patients  were  included.  Baseline  clinical  characteristics
are  shown  in  Table  1.  Most  patients  (n  =  157,  83.5%)  were
men;  the  median  age  was  51.5  (46.0—57.0)  years.  One
hundred  and  forty-eight  (78.7%)  patients  were  objectively
hypertensive,  whereas  70  of  them  (47.2%)  reported  known
hypertension.  Half  of  the  hypertensive  patients  presented  a
non-dipper  proﬁle  on  data  from  ABPM.  As  an  inclusion  crite-
rion,  all  patients  had  OSAS;  165  (87.8%)  were  already  treated
for  OSAS,  mostly  with  continuous  positive  airway  pressure
(CPAP;  n  =  158,  84.5%).  The  median  AHI  was  48.4  (32.0—71.0)
events/hour  and  most  patients  had  severe  OSAS,  with  AHI
>30  events/hour  (n  =  159,  84.6%).  All  of  them  presented  a
sinus  rhythm.
Left ventricular geometry
Echocardiographic  characteristics  are  shown  in  Table  2.
Nineteen  (10.1%)  patients  had  inadequate  two-dimensional
images  for  assessment  of  LV  mass  and  geometry.  Among  the
169  remaining  patients,  the  prevalence  of  LVH  was  different
according  to  the  corrective  factor  used  (BSA  or  height2.7):
6.5%  if  LVMi  normalized  by  BSA;  12.4%  if  normalized  by
height2.7.  In  the  latter  case,  LVH  was  mostly  eccentric  (n  =  14
f
f
T
aOnly available for patients without missing data.
ccentric  versus  n  =  7  concentric).  LV  geometry  was  normal
or  136  (80.5%)  patients  with  LVMi  corrected  by  BSA,  and
or  127  (75.2%)  patients  with  LVMi  corrected  by  height2.7.
here  was  a signiﬁcant  correlation  between  hypertension
nd  LV  geometry,  but  only  if  assessed  by  LVMi  normalized
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Table  2  Baseline  echocardiographic  characteristics.
Characteristic  OSAS  patients  (n  =  188)
LVEF  <50%  3  (1.6)
LVH  (BSA;  n  =  169)  11  (6.5)a
LVH  (height2.7;  n  =  169)  21  (12.4)a
LVMi  (n  =  169)
Normalized  by  BSA  76.9  (67.7—88.1)a
Normalized  by  height2.7 35.9  (30.3—43.7)a
LVEDD  (mm;  n  =  185) 51.3 (48.0—54.7)a
LVESD  (mm;  n  =  186) 33.0 (29.2—36.8)a
RWT  (n  =  169)  0.35  (0.31—0.39)a
LV  geometry  (BSA;  n  =  169)
Normal  136  (80.5)a
Concentric  remodelling  22  (13.0)a
Concentric  hypertrophy  6  (3.6)a
Eccentric  hypertrophy  5  (3.0)a
LV  geometry  (height2.7;  n  =  169)
Normal  127  (75.2)a
Concentric  remodelling 21  (12.4)a
Concentric  LVH  7  (4.1)a
Eccentric  LVH  14  (8.3)a
LAA  (cm2;  n  =  168)  17.9  (15.3—20.8)a
LAV  (mL/m2;  n  =  94)  22.9  (18.8—29.2)a
Pulmonary  hypertension
(n  =  178)
11  (5.9)a,b
Diastolic  function  variables
Lateral  e′ velocity
(n  =  169)
0.11  (0.09—0.12)a
E/A  ratio  1.06  (0.88—1.23)
E-wave  deceleration
time  (n  =  172)
184.3  (164.8—204.5)a
E/e′ ratio  (n  =  169)  7.0  (5.7—8.3)a
pA-mA  duration  (n  =  156)  −33.5  (−46.5—−17.3)a
Diastolic  function  by  a  standardized  approach
Normal  diastolic
function
118  (62.8)
Abnormal  diastolic
function
70 (37.2)
Data are expressed as number (%) or median (interquartile
range). BSA: body surface area; E/A: early/late diastolic mitral
peak ﬂow velocity ratio; E/e′: mitral early diastolic peak ﬂow
velocity/early diastolic velocity by TDI ratio; LAA: left atrial
area; LAV: left atrial volume; LV: left ventricular; LVEDD:
left ventricular end diastolic diameter; LVEF: left ventricular
ejection fraction; LVESD: left ventricular end systolic diameter;
LVH: left ventricular hypertrophy; LVMi: left ventricular mass
index; mA: late diastolic mitral pulse-wave velocity duration;
pA: late diastolic pulmonary pulse-wave velocity duration; RWT:
relative wall thickness.
a Only available for patients without missing data.
b Pulmonary hypertension deﬁned by systolic pulmonary arterial
pressure ≥45 mmHg for seven patients, and by mean pulmonary
arterial pressure ≥25 mmHg for four patients.
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y  height2.7 (P  =  0.004;  Table  3).  We  did  not  observe  a  sig-
iﬁcant  difference  in  LV  geometry  according  to  the  type  of
ypertension  (known,  masked  or  absent)  or  according  to  its
roﬁle  (dipper  or  non-dipper;  data  not  shown).
Correlations  between  AHI  and  desaturation  time  on  the
ne  hand,  and  clinical  and  echocardiographic  characteris-
ics  on  the  other  hand,  are  shown  in  Supplementary  data,
ables  S1  and  S2, respectively.  AHI  correlated  signiﬁcantly
ith  BMI,  triglycerides,  desaturation  time  and  24-hour  SBP
ecause  of  night  SBP  (Supplementary  data,  Table  S1).
oncerning  echocardiographic  characteristics,  AHI  corre-
ated  signiﬁcantly  with  LAA  and  LVMi  only  if  normalized
y  height2.7 (Supplementary  data,  Table  S2).  However,  only
MI  and  desaturation  time  exhibited  relevant  correlation
oefﬁcients  (0.36  and  0.56,  respectively).  About  desatura-
ion  time,  we  did  not  observe  any  correlation  with  night  SBP,
ut  correlations  with  fasting  glycaemia,  LV  diameters  and
VMi  (normalized  by  height2.7) were  statistically  signiﬁcant.
ll  correlation  coefﬁcients  were  <0.5.
eft ventricular diastolic function
egarding  LV  function,  only  three  (1.6%)  patients  presented
V  systolic  dysfunction,  which  was  moderate  in  two  cases
LVEF  ≥45%).  By  a standardized  approach  using  a  decisional
ree,  70  patients  presented  abnormal  diastolic  function
37.2%;  Fig.  1  and  Table  2).  Baseline  characteristics  of
atients  according  to  the  diastolic  function  classiﬁcation
normal  diastolic  function,  diastolic  dysfunction  grade  I,
rade  II,  grade  III)  are  shown  in  Table  4.  Fig.  2  shows  respira-
ory  severity  variables  across  the  four  groups.  Among  the  34
atients  without  hypertension,  diabetes,  severe  obesity  and
VH,  ﬁve  (17%)  patients  presented  LV  diastolic  dysfunction.
Logistic  regression  analyses,  using  diastolic  dysfunction
ssessed  by  a  standardized  approach  as  a  dependent  vari-
ble,  are  shown  in  Table  5.  Two  models  are  presented,
ccording  the  corrective  factor  used  for  the  LVMi  (BSA  or
eight2.7).  The  univariate  analysis  showed  that  age,  pres-
nce  of  hypertension  and  24-hour  SBP  were  predictors
f  diastolic  dysfunction.  The  multivariable  analyses,  after
djustment  for  age  and  sex  and  stepwise  regression,  showed
hat  severity  variables  of  OSAS  and  LVMi,  whatever  the  cor-
ective  factor  used,  were  not  independent  predictors  of
iastolic  dysfunction.
iscussion
his  retrospective  study  reports  the  clinical  and  echocardi-
graphic  characteristics  of  a  real-life  large  cohort  of  OSAS
atients,  focusing  on  diastolic  function  assessed  by  a  stan-
ardized  approach.
eft ventricular geometry
ur  results  show  different  rates  of  LVH  depending  on
hether  LVMi  was  normalized  by  BSA  or  height2.7. Indeed,
he  prevalent  LVH  was  twice  as  high  if  LVMi  was  corrected
y  height2.7.  These  data  are  consistent  with  those  reported
y  de  Simone  et  al.  [23], who  found  that  LVH  was  under-
stimated  in  obese  patients  if  assessed  by  LVMi  normalized
y  BSA  or  body  weight,  and  who  recommend  LVM  indexation
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Table  3  Left  ventricular  geometry  according  to  the  presence  of  hypertension.
Hypertension  (n  =  125)  No  hypertension  (n  =  44)  P
LV  geometry  (BSA)  0.09
Normal  99  (79.2)  37  (84.1)
LVH  11  (8.8)  0
Concentric  remodelling  15  (12.0)  7  (15.9)
LV  geometry  (height2.7)  0.004
Normal  90  (72.0)  37  (84.1)
LVH 21  (16.8) 0
Concentric  remodelling 14  (11.2) 7  (15.9)
Data are expressed as number (percentage). BSA: body surface area; LV: left ventricular; LVH: left ventricular hypertrophy.
Figure 1. Decisional tree of diastolic function evaluation by standardized approach. DT: desaturation time; e′: early diastolic mitral
/late
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[annular velocity; E/A ratio: early diastolic mitral peak ﬂow velocity
diastolic mitral pulse-wave velocity duration; pA: late diastolic pul
method  based  on  obesity-independent  measure  of  body  size.
Indeed,  more  than  half  of  our  patient  cohort  were  obese,  as
in  most  OSAS  patient  cohorts  [5].  Given  that  LV  geometry
has  a  well-known  prognostic  value,  and  that  LVH  assessed
by  LVMi  (height2.7)  is  a  stronger  independent  predictor  of
incident  cardiovascular  diseases  than  LVMi  (BSA)  [29],  these
results  conﬁrm  that  the  use  of  LVMi  corrected  by  height2.7
is  the  appropriate  method  for  assessment  of  LV  geometry
in  OSAS  patients.  Furthermore,  we  observed  a  signiﬁcant
association  between  hypertension  and  LVMi  normalized  by
height2.7.  Despite  the  high  prevalence  of  hypertension  in  our
cohort,  we  observed,  like  Baguet  et  al.  [30],  a  lower  rate  of
LVH  than  previously  reported,  with  a  large  majority  having
normal  LV  geometry.  Indeed,  in  a  large  cross-sectional  anal-
ysis  based  on  the  Sleep  Heart  Health  Study,  Chami  et  al.
[31]  reported  an  LVH  prevalence  of  up  to  33%  according  to
the  severity  of  OSAS  and  the  type  of  LVH;  likewise,  Noda
o
t
c
r diastolic mitral peak ﬂow velocity; LAA: left atrial area; mA: late
ry peak ﬂow velocity.
t  al.  [32]  reported  an  LVH  prevalence  of  41.2%  in  51  mild-
o-severe  OSAS  patients.  Explanations  for  this  discrepancy
ight  be  the  young  age  and  the  low  severity  of  hypertension
n  the  present  cohort,  with  a  mean  24-hour  SBP  of  130  mmHg
nd  a  mean  24-hour  DBP  of  78  mmHg,  whereas  hypertension
s  a major  confounding  factor  of  LVH  in  OSAS  populations
30,32].  However,  Koga  et  al.  [33]  found  only  5%  with  nor-
al  LV  geometry  in  37  OSAS  men  presenting  the  same  clinical
aseline  characteristics  as  those  in  the  present  study.  Yet,
n  the  study  by  Koga  et  al.,  patients  did  not  undergo  ABPM;
his  might  underestimate  the  prevalence  of  hypertension.
oreover,  in  a  large  cross-sectional  study,  Niroumand  et  al.
15]  found  that  OSAS  does  not  increase  LVM  independently
f  obesity,  hypertension  or  advanced  age.  That  is  consis-
ent  with  our  results,  where  OSAS  severity  variables  did
orrelate  with  LVMi  normalized  by  height,  but  with  a  poorly
elevant  correlation  coefﬁcient  (r2 =  0.039).  Nevertheless,
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Table  4  Patient  characteristics  according  to  diastolic  function  class.
Characteristics  Normal  (n  =  118)  Dysfunction
grade  I  (n  =  21)
Dysfunction
grade  II  (n  =  48)
Dysfunction
grade  III
(n  =  1)
Clinical
Men  101  (85.6)  18  (85.7)  38  (79.2)  0  (0)
Age  (years)  50.0  (44.0—55.0)  60.0  (54.0—62.5)  52.0  (46.3—59.3)  43.0
Hypertension  85  (72) 20  (95.2)  42  (87.5)  1  (100)
Known  hypertension 36  (30.5) 11  (11.2) 23  (47.9)  0  (0)
Masked  hypertension 29  (24.6) 7  (33.3) 7  (14.6) 1  (100)
Nocturnal
hypertension  (n  =  185)a
63  (53.8) 12  (60.0) 37  (78.7) 0  (0)
Diurnal  hypertension  69  (58.5)  15  (71.4)  35  (72.9)  1  (100)
Non-dipper  (n  =  185)a 55  (46.6)  11  (52.4)  24  (50.0)  0  (0)
Diabetes  13  (11.0)  2  (9.5)  8  (16.7)  0  (0)
Metabolic  syndrome 43  (36.4) 8  (38.1) 29  (60.4) 0  (0)
Current  smoker 33  (28.0) 5  (23.8) 10  (20.8) 0  (0)
Obesity  63  (53.4)  9  (42.9)  32  (66.7)  1  (100)
BMI  (kg/m2)  30.9  (26.8—35.2)  28.1  (26.8—33.8)  32.1  (28.7—36.5)  45.4
Fasting  glycaemia
(mmol/L;  n  =  183)a
5.2  (4.8—5.7)  5.4  (5.0—5.7)  5.5  (4.8—6.1)  5.4
Triglycerides  (g/L;
n  =  184)a
1.21  (0.93—1.70)  1.04  (0.88—1.67)  1.31  (1.03—2.00)  1.09
Creatinine  (mol/L;
n  =  185)a
94  (85—103)  98  (89—108)  91  (83—101)  58
OSAS  treatment,  yes  105  (89.0)  19  (90.5)  40  (83.3)  1  (100)
Treatment  with  CPAP
(n  =  187)a
99  (83.9)  18  (90.0)  40  (83.3)  1  (100)
AHI  (events/hour)  47.5  (33.8—69.3)  45.0  (22.5—67.0)  49.5  (30.1—74.5)  121
Desaturation  time  (%;
n  =  180)a
7  (2—23)  12  (5—33)  6  (0.1—30)  66
Epworth  sleepiness
score  (n  =  178)a
10  (7—14)  12  (5—17)  11  (8—15)  5
24-hour  heart  rate
(bpm)
74  (68—81)  74  (67—82)  73  (69—84)  78
24-hour  SBP  (mmHg) 129  (121—139) 134  (125—147)  131  (125—145)  125
24-hour  DBP  (mmHg) 78  (73—83) 83  (77—89) 79  (73—86)  72
Echocardiographic
LVEF  <50%  1  (0.8)  0  2  (4.2)  0
LVH  (BSA;  n  =  169)a 5  (4.7)  2  (10.5)  3  (7.0)  1  (100)
LVH  (height2.7;  n  =  169)a 10  (9.4)  4  (21.0)  6  (13.9)  1  (100)
LVMi  (n  =  169)
Normalized  by  BSA  75.7  (65.9—87.8)  75.4  (60.1—91.5)  79.3  (70.4—94.0)  100.4
Normalized  by
height2.7
35.2  (30.3—43.2)  36.0  (28.4—44.9)  36.8  (32.0—46.4)  61.5
LVEDD  (mm;  n  =  185)a 51.0  (48.0—54.7)  48.9  (44.8—55.7)  52.0  (48.0—55.3)  50.0
LVESD  (mm;  n  =  186)a 32.9  (28.7—36.5)  32.8  (28.8—37.9)  33.2  (29.5—37.2)  34.0
RWT  (n  =  169)a 0.34  (0.30—0.38)  0.37  (0.34—0.46)  0.36  (0.30—0.39)  0.43
LV  geometry  (BSA;
n  =  169)a
Normal  89  (84.0)  11  (57.9)  36  (83.7)  0
Concentric
remodelling
12  (11.3)  6  (31.6)  4  (9.3)  0
Concentric
hypertrophy
3  (2.8)  1  (5.3)  1  (2.3)  1  (100)
Eccentric  hypertrophy  2  (1.9)  1  (5.3)  2  (4.7)  0
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Table  4  (Continued)
Characteristics  Normal  (n  =  118)  Dysfunction
grade  I  (n  =  21)
Dysfunction
grade  II  (n  =  48)
Dysfunction
grade  III
(n  =  1)
LV  geometry  (height2.7;
n  =  169)a
Normal  84  (79.2)  10  (52.6)  33  (76.7)  0
Concentric
remodelling
12  (11.3)  5  (23.8)  4  (9.3)  0
Concentric  LVH  3  (2.8)  2  (10.5)  1  (2.3)  1  (100)
Eccentric  LVH  7  (6.6)  2  (10.5)  5  (11.6)  0
LAA  (cm2;  n  =  168)a 17.6  (15.2—20.4)  18.2  (15.3—23.2)  18.1  (15.8—20.9)  18.0
LAV  (mL/m2;  n  =  94)a 22.3  (18.8—29.1)  22.1  (18.0—36.7)  23.7  (17.8—32.2)  —
Pulmonary  hypertension
(n  =  178)a
5  (4.2)  2  (9.5)  4  (8.3)  0
Diastolic  function
variables
Lateral  e′ velocity
(n  =  169)a
0.12  (0.11—0.13)  0.07  (0.06—0.08)  0.08  (0.08—0.09)  0.09
E/A  ratio  1.11  (0.94—1.29)  0.68  (0.58—0.74)  1.00  (0.91—1.16)  2.09
E-wave  deceleration
time  (n  = 172)a
183.7  (166.7—201.7)  203.5  (183.0—242.9)  179.7  (163.0—200.9)  145
E/e′ ratio  (n  =  169)a 6.1  (5.3—7.4)  8.6  (6.4—9.6)  8.5  (7.6—11.0)  10.9
pA-mA  duration
(n  =  156)a
−34.3  (−47.0—−20.7)  −37.3  (−49.5—−9.7)  −26.7  (−44.3—−11.8)  —
Data are expressed as number (%) or median (interquartile range). BSA: body surface area; E/A: early/late diastolic mitral peak ﬂow
velocity ratio; E/e′: mitral early diastolic peak ﬂow velocity/early diastolic velocity by TDI ratio; LAA: left atrial area; LAV: left atrial
volume; LVEDD: left ventricular end diastolic diameter; LVEF: left ventricular ejection fraction; LVESD: left ventricular end systolic
diameter; LVH: left ventricular hypertrophy; LVMi: left ventricular mass index; mA: late diastolic mitral pulse-wave velocity duration;
pA: late diastolic pulmonary pulse-wave velocity duration; RWT: relative wall thickness.
a Only available for patients without missing data.
Figure 2. Apnoea-hypopnoea index and desaturation time across
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studies,  associations  were  reported  between  OSAS  severitydiastolic function classiﬁcation. AHI: apnoea-hypopnoea index. Data
are expressed as median (interquartile range).
we  must  mention  several  studies  reporting  a  signiﬁcant  cor-
relation  between  LVMi  and  severity  of  OSAS,  even  after
adjustment  for  the  main  confounding  factors  [15,31]  or  in
the  speciﬁc  context  of  heart  failure  [34].  Besides,  from  one
study  to  another,  the  results  of  prevalent  LVH  may  be  very
different  depending  on  the  methods  used.  Indeed,  Noda
et  al.  deﬁned  LVH  according  to  interventricular  septum  or
a
w
[osterior  wall  thickness,  without  LVM  calculation  [32].  Like-
ise,  several  studies  assessed  LVH  by  LVMi  normalized  by
SA  only  [12—14,35]. Finally,  LVH  deﬁned  using  LVMi  normal-
zed  by  height  was  more  often  eccentric  than  concentric,
s  found  by  Chami  et  al.  [31],  with  a signiﬁcant  correla-
ion  between  LV  diameters  and  desaturation  time  but  not
HI.
eft ventricular diastolic function
e  found  that  62.8%  of  our  patients  had  normal  LV  diastolic
unction,  assessed  by  a  standardized  approach,  and  that  age
as  the  only  independent  predictor  of  diastolic  function.
SAS  severity  variables  were  not  associated  with  diastolic
ysfunction.  Likewise,  Spearman’s  correlation  analysis  did
ot  show  any  correlation  between  different  variables  of
iastolic  function  evaluation  and  AHI  or  desaturation  time,
uggesting  that  LV  diastolic  dysfunction  is  chieﬂy  related  to
o-morbidities.  These  results  are  consistent  with  a  previ-
us  large  cross-sectional  study  by  Niroumand  et  al.,  who
ound  no  signiﬁcant  difference  in  the  E/A  ratio  between
SAS  and  non-OSAS  patients  [15].  However,  in  several  othernd  E/A  ratio  [35,36],  A  peak  wave  [36]  or  LA  volume  [37],
ith  reversibility  after  a  few  months  of  CPAP  treatment
33,37,38].  Furthermore,  AHI  was  signiﬁcantly  correlated
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Table  5  Predictors  of  left  ventricular  diastolic  dysfunction.
Univariate  regression  Multivariable
regression  using  LVMi
normalized  by  BSA
Multivariable
regression  using  LVMi
normalized  by  height2.7
OR  (95%  CI)  P  OR  (95%  CI)  P  OR  (95%  CI)  P
LVMi,  per  5  units  increase
Normalized  by  BSA  1.08  (0.99—1.18)  0.10  1.03
(0.94—1.14)
0.51  —  —
Normalized  by  height2.7 1.16  (1.00—1.37)  0.06  —  —  1.08
(0.90—1.28)
0.42
Age  1.07  (1.03—1.11) 0.001 1.06
(1.02—1.10)
0.004 1.06
(1.02—1.10)
0.004
Male  0.68  (0.30—1.54)  0.36  —  —  —  —
Hypertension,  yes  2.50  (1.14—5.51)  0.023  1.88
(0.81—4.40)
0.14  1.79
(0.75—4.28)
0.19
Hypertension,  known  3.01  (1.32—6.89)  0.009  —  —  —  —
Hypertension,  masked 1.70  (0.66—4.41)  0.28  —  —  —  —
Diurnal  hypertension,  yes  1.71  (0.86—3.37)  0.12  —  —  —  —
Nocturnal  hypertension,
yes  (n  =  166)
2.02 (1.02—3.98)a 0.043  —  —  —  —
Non-dipper,  yes  (n  =  166)  1.28  (0.68—2.42)a 0.44  —  —  —  —
Diabetes,  yes 1.46 (0.59—3.61) 0.41 —  —  —  —
Metabolic  syndrome,  yes  1.57  (0.84—2.95)  0.16  —  —  —  —
Current  smoker,  yes  0.80  (0.38—1.66)  0.54  —  —  —  —
BMI,  per  unit  increase  1.00  (0.95—1.05)  0.97  —  —  —  —
AHI,  after  log
transformation
0.88 (0.52—1.48)  0.62  —  —  —  —
Desaturation  time,  after
log  transformation
(n =  161)
0.97  (0.78—1.19)a 0.76  —  —  —  —
24-hour  heart  rate,  per  5
units  increase
1.06  (0.90—1.23)  0.49  —  —  —  —
24-hour  SBP,  per  5  units
increase
1.15  (1.02—1.31)  0.021  —  —  —  —
24-hour  DBP,  per  5  units
increase
1.18  (0.97—1.44)  0.10  —  —  —  —
AHI: apnoea-hypopnoea index; BMI: body mass index; BSA: body surface area; DBP: diastolic blood pressure; OR (95% CI): odds ratio
(95% conﬁdence interval); SBP: systolic blood pressure.
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ith  LAA,  which  is  a  surrogate  for  diastolic  function.
owever,  the  correlation  coefﬁcient  was  not  sufﬁciently
linically  relevant,  and  we  did  not  observe  such  a  correla-
ion  with  desaturation  time.  Finally,  to  our  knowledge,  this
s  the  ﬁrst  study  to  take  a  multivariable  approach  to  the
ssessment  of  diastolic  function  in  OSAS  patients.  Yet,  OSAS
atients  often  present  normal  LV  systolic  function  or  LVH,
wo  conditions  where  the  use  of  mitral  inﬂow  only  is  known
o  be  inadequate  because  of  a  poor  correlation  between
itral  ﬂow  pattern  and  haemodynamics  [25].
n
a
i
ttudy limitations
his  study  has  several  limitations.  First,  it  was  a  single-
entre  uncontrolled  study.  Our  ﬁndings  cannot  necessarily
e  extrapolated  to  OSAS  populations  with  less  severe  respi-
atory  diseases,  and  severity  of  OSAS  in  this  cohort  did
ot  allow  to  perform  comparisons.  However,  the  lack  of
 control  group  does  not  alter  the  demonstration  of  an
ndependent  relationship  between  LVMi  (height)  and  hyper-
ension  on  the  one  hand,  and  between  diastolic  dysfunction
a  sy
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and  hypertension  on  the  other.  Moreover,  the  high  severity  of
OSAS  reported  in  this  cohort  makes  us  able  to  highlight  a  link
between  severity  variables  and  diastolic  dysfunction  without
powerfulness.  Furthermore,  the  very  low  frequency  in  this
population  of  co-morbidities  known  to  be  confounding  fac-
tors  that  lead  to  diastolic  dysfunction  (diabetes,  atrial  ﬁbril-
lation,  LVH)  allows  us  to  focus  on  OSAS  variables  as  an  inde-
pendent  effect,  and  may  partly  explain  our  negative  results.
Second,  we  did  not  consider  the  durations  of  OSAS  or
CPAP  treatment.  Thus,  the  low  rate  of  LVH,  and  the  preva-
lence  of  LV  diastolic  dysfunction  and  its  correlation  with
OSAS,  may  be  partly  explained  by  a  short  duration  of  evolu-
tion  in  some  cases  and  by  a  partial  reversibility  after  CPAP
treatment  [33,38,39].  However,  in  most  cases,  patients  were
referred  after  the  ﬁrst  sleep  study,  limiting  the  recruitment
of  patients  with  OSAS  of  long  duration.
Lastly,  as  guidelines  for  diastolic  function  evaluation
recommending  the  use  of  the  average  of  septal  and  lateral
e′ velocities  were  published  in  2009,  4  years  after  the  begin-
ning  of  this  study,  only  lateral  mitral  annular  velocities  were
recorded.
Conclusions
In  this  observational  study,  we  found  a  signiﬁcant  associa-
tion  between  hypertension  and  LVMi  corrected  for  height2.7.
We  used  a  global  standardized  approach  to  assess  the  preva-
lence  of  diastolic  dysfunction  (37%)  in  a  real-life  cohort  of
OSAS  patients.  However,  OSAS  was  not  a  predictor  of  LV
diastolic  dysfunction  in  multivariable  analysis.  Given  that
both  LVH  and  diastolic  dysfunction  have  important  progno-
stic  value,  these  results  conﬁrm  the  usefulness  of  a  complete
cardiovascular  evaluation  in  patients  with  OSAS,  but  need  to
be  supported  by  controlled  comparative  studies.
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